Table 2.
Selected clinical characteristic of the sample, and outcomes, overall and by type of anti-IL23.
| Variables | Overall sample (n=427) | Guselkumab (n=201) | Risankizumab (n=116) | Tildrakizumab (n=110) | p * |
|---|---|---|---|---|---|
| Mean duration of anti-IL 23 treatment in months (SD)A | 18.9 (10.8) | 22.2 (11.7) | 15.9 (7.5) | 15.8 (10.4) | a, b |
| Drug survival, % | 94.6 | 95.0 | 96.6 | 91.7 | |
| Mean PASI at baseline (SD) | 12.9 (7.3) | 13.5 (7.6) | 11.9 (7.1) | 12.9 (6.8) | |
| Mean PASI at week 12 (SD) | 2.8 (3.4) | 2.2 (2.1) | 1.5 (2.7) | 4.1 (4.5) | |
| Mean PASI % reduction between baseline and week 12, (SD) | 77.8 (25.9) | 82.2 (18.7) | 89.8 (20.5) | 67.4 (31.4) | b, c |
| Baseline-week 12 PASI reduction ≥75%, % | 63.3 | 67.3 | 86.1 | 48.8 | a, b, c |
| Baseline-week 12 PASI reduction ≥90%, % | 45.0 | 45.8 | 72.2 | 32.6 | a, c |
| Baseline-week 12 PASI 100% decrease, % | 34.1 | 30.8 | 69.4 | 23.3 | a, b, c |
| Mean PASI at week 16 (SD) | 1.8 (3.0) | 1.6 (2.4) | 1.2 (2.5) | 4.4 (5.1) | b, c |
| Mean PASI % reduction between baseline and week 16, (SD) | 81.9 (39.5) | 82.6 (41.3) | 86.6 (30.4) | 64.5 (51.0) | |
| Baseline-week 16 PASI 90% decrease, % | 64.7 | 64.9 | 75.0 | 33.3 | b, c |
| Baseline-week 16 PASI 100% decrease, % | 47.4 | 39.2 | 68.2 | 26.7 | a, c |
| Mean PASI at week 28 (SD) | 1.5 (3.3) | 1.2 (2.9) | 1.5 (2.8) | 1.9 (4.0) | |
| Mean PASI % reduction between baseline and week 28, (SD) | 86.0 (33.3) | 86.3 (40.3) | 83.1 (32.5) | 87.4 (19.3) | |
| Baseline-week 28 PASI reduction ≥75%, % | 83.9 | 87.9 | 78.3 | 81.4 | |
| Baseline-week 28 PASI 90% decrease, % | 73.2 | 76.9 | 69.6 | 70.0 | |
| Baseline-week 28 PASI 100% decrease, % | 57.1 | 61.1 | 60.9 | 48.6 |
SD: Standard deviation; PASI: Psoriasis area severity index.
A
Patients not withdrawn from anti-IL 23 treatment only.
*
Chi-squared test for categorical variables; one-way ANOVA with Sidak corrections for continuous ones.
a: p<0.05 for the comparison between patients treated with Guselkumab and patients treated with Risankizumab; b: p<0.05 for the comparison between patients treated with Guselkumab and patients treated with Tildrakizumab; c: p<0.05 for the comparison between patients treated with Risankizumab and patients treated with Tildrakizumab. All p-values that are not indicated were ≥0.05.